Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 13, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Pathologic findings and outcomes for octogenarians presenting with uterine malignancy.

Kathleen N Moore1, Grainger S Lanneau, Chad Smith

  • 1University of Oklahoma Division of Gynecologic Oncology, 920 SL Young Blvd., Oklahoma City, OK 73103, USA. Kathleen-moore@ouhsc.edu

Gynecologic Oncology
|July 10, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same author

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer.

Nature reviews. Clinical oncology·2026
Same author

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Nature reviews. Clinical oncology·2026
Same author

Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.

Gynecologic oncology·2026
Same author

Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].

Gynecologic oncology·2026

Elderly patients with uterine cancer (UC) show good two-year survival, even with no adjuvant therapy. Medical conditions may affect survival more than recurrence risk in this population.

Area of Science:

  • Gynecologic Oncology
  • Geriatric Medicine
  • Cancer Research

Background:

  • Uterine cancer (UC) in elderly patients (>80 years) presents unique prognostic and demographic challenges.
  • Comorbidities are common in this age group and may influence treatment decisions and outcomes.

Purpose of the Study:

  • To evaluate prognostic, demographic, and outcome data for elderly patients diagnosed with uterine cancer.
  • To assess the survival and recurrence patterns in Stage I uterine cancer patients over 80.

Main Methods:

  • Retrospective review of clinical records for patients over 80 with uterine cancer.
  • Statistical analysis using Fisher's exact test for categorical data and Kaplan-Meier for survival data.

Main Results:

Related Experiment Videos

Last Updated: Jul 13, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

  • Sixty-five elderly patients (mean age 84) with UC were analyzed; 65% had comorbidities.
  • Stage I UC patients, both clinically and surgically staged, demonstrated excellent two-year overall survival (77%) despite no adjuvant therapy.
  • Among high-intermediate risk patients, recurrence was low (16%), and locoregional recurrence was minimal (5%).

Conclusions:

  • Elderly patients with UC may exhibit characteristics linked to extrauterine spread.
  • Observation appears to be an acceptable approach for elderly Stage I UC patients, given the low recurrence rates observed.
  • Medical comorbidities may be a more significant factor in survival than recurrence risk for this demographic.